Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc., No. 14-1391 (Fed. Cir. Dec. 3, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent case involves methods of use of nanosized formulations of the drug megestrol a cetate (“megestrol”). After a bench trial, the U.S. District Court for the District of Maryland found the asserted claims of U.S. Patent No. 7,101,576 (“’576 patent”) invalid as obvious. We vacate the district court’s judgment of invalidity and remand fo r further analysis because the district court incorrectly applied our law on inherency in the context of obviou s- ness. I.